|
|
Ani Pharmaceuticals inc (ANIP) |
|
Price: $48.0000
$1.58 
3.404%
|
| Day's High:
| $48.04
| Week Perf:
| 4.01 %
|
| Day's Low: |
$ 46.13 |
30 Day Perf: |
26.35 % |
| Volume (M): |
166 |
52 Wk High: |
$ 52.23 |
| Volume (M$): |
$ 7,954 |
52 Wk Avg: |
$37.69 |
| Open: |
$46.79 |
52 Wk Low: |
$22.31 |
|
|
| Market Capitalization (Millions $) |
793 |
| Shares
Outstanding (Millions) |
17 |
| Employees |
685 |
| Revenues (TTM) (Millions $) |
359 |
| Net Income (TTM) (Millions $) |
-26 |
| Cash Flow (TTM) (Millions $) |
-14 |
| Capital Exp. (TTM) (Millions $) |
17 |
Ani Pharmaceuticals Inc
Ani Pharmaceuticals Inc. is an innovative specialty pharmaceutical company that focuses on the development, manufacturing, and commercialization of high-quality generic and branded prescription pharmaceuticals. The company was founded in 2002 and is headquartered in Baudette, Minnesota, United States.
Ani Pharmaceuticals operates in four main segments: Generic Pharmaceuticals, Branded Pharmaceuticals, Contract Manufacturing, and Specialty Pharmaceuticals. The Generic Pharmaceuticals segment develops and markets generic products that are equivalent to their brand-name equivalents but are lower-priced alternatives. The Branded Pharmaceuticals segment focuses on branded products that are marketed to specific niche markets, usually where there are no generic alternatives. The Contract Manufacturing segment provides contract manufacturing services to other pharmaceutical companies, utilizing the company's expertise in formulation development, analytical testing, and commercial-scale manufacturing. The Specialty Pharmaceuticals segment develops and markets specialty products that typically have lower competition, smaller markets, and higher margins than generic or branded products.
Ani Pharmaceuticals has a portfolio of over 100 generic and branded products covering several therapeutic categories, including oncology, cardiology, dermatology, pain management, and more. It markets its products through wholesalers, distributors, retailers, and other customers in the United States, Canada, and other international markets.
Apart from its product portfolio, Ani Pharmaceuticals has a state-of-the-art FDA-approved manufacturing facility that can produce several dosage forms such as tablets, capsules, creams, gels, and liquids. The company has a highly experienced team of scientists, researchers, and technicians who work relentlessly to develop new and innovative products that meet the evolving needs of the healthcare industry.
Ani Pharmaceuticals is committed to achieving high levels of growth through organic growth and strategic partnerships and acquisitions. The company has made several strategic acquisitions over the years to expand its product pipeline and enhance its manufacturing capabilities. It also partners with other pharmaceutical companies to develop and commercialize joint products.
In summary, Ani Pharmaceuticals Inc. is a leading specialty pharmaceutical company with a strong focus on the development, manufacturing, and commercialization of high-quality generic and branded prescription pharmaceuticals. The company has a diversified product portfolio, state-of-the-art manufacturing facility, and a highly experienced team of experts. It is committed to innovation, growth, and exceeding the expectations of its customers, employees, and shareholders.
Company Address: 210 Main Street West Baudette 56623 MN
Company Phone Number: 634-3500 Stock Exchange / Ticker: NASDAQ ANIP
| ANIP is expected to report next financial results on August 07, 2023. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Lifecore Biomedical Inc
The pharmaceutical industry is a vital sector in the global economy. It is responsible for producing lifesaving drugs, vaccines, and other medical products that improve the lives and health of people globally. However, like any other industry, the pharmaceutical industry also faces its own set of challenges. These challenges range from regulatory and compliance issues to stiff competition and changing market dynamics.
Recently, one of the major pharmaceutical companies shared some good news. The company proclaimed record revenues of $27.6 million in the fiscal year ending February 26, 2023. This achievement is commendable, considering the challenges the pharmaceutical industry faces. However, another company in the sector, Lifecore Biomedical Inc, reported a net deficit of $-40.192 million in the same reporting season.
|
|
Globestar Therapeutics Corporation
The financial results for the Globestar Therapeutics Corporation (GSTC) for the January to March 31, 2023 reporting cycle have been released, and shareholders were not expecting any moderations at the top-line. However, it appears that they are paying a significant amount of attention to the company's operating shortfall, which was reported at $-0.142059 million during the same period. One positive aspect of this result is that it compares favorably to the performance of the second quarter of 2022, where the operating shortfall was significantly higher at $-0.66231 million. This appears to be a significant indicator for the company's course going forward.
For a company like GSTC, which is on an upward trajectory in terms of revenue generation, it becomes increasingly important to run cost-effectively in order to reach the next chapter of its growth. The good news is that there has been some alleviation on the bottom-line, as the diminishing returns have been cut from the same time frame a year prior. The fiscal span ending in the second quarter of 2023 saw a loss of $-0.150 million, which is lower than the loss of $-0.689 million reported in the same period in 2022. This is a major takeaway from the most recent financial results, which indicates that GSTC is moving in the right direction, albeit at a steady pace.
|
|
Q Biomed Inc
For the fourth quarter of 2022 earnings season Q Biomed Inc had turn a round to surplus by exhibiting earnings per share of $0.02 per share compare to $-0.08 a year before and earnings per share turned positive from $-0.03 per share from the prior financial reporting period. The revenue went down sharply by -88.053 % to $0.01 million from $0.10 million in the comparable financial reporting period a year before and sequentially Revenue Tumbled by -52.286 % from $0.03 million.
|
|
23andme Holding Co
23andme Holding Co Posts Mixed Q4 Results, Despite Lower Demand
23andme Holding Co, the popular genetic testing company, has released its latest earnings report for Q4 2023. In a disappointing development for investors, the company's revenue was hit hard by lower demand, leading to a vanishing revenue and higher deficit.
While the earnings report may have been mixed, there was some positive news to report. The company announced that it had been able to decrease its loss per share to $-0.13 per share, which may be seen as an encouraging sign to some investors. However, revenue decreased by -8.137% to $92.38 million, signifying that the company still has some way to go in order to generate more growth.
|
|
Shuttle Pharmaceuticals Holdings Inc
As the earnings season for January to March 31, 2023, continues, many corporations have announced their respective results. The pharmaceutical industry, a significant player in the global market, has also been reporting their earnings. One company that has recently released its earnings report is Shuttle Pharmaceuticals Holdings Inc.
Shuttle Pharmaceuticals Holdings Inc (SHPH), a rising player in the industry, has issued an operating deficit of $-1.54478 million for the first quarter of the 2023 earnings season. While the shareholders anticipate additional revenue sources to evolve in the near future, they are less interested in the corporation's current accomplishment.
It is not surprising that the company realized a net loss of $-0.975 million, which has extended from $-0.078 million in the financial quarter ending March 31, 2022. The shareholders' expectations of additional revenue streams reflect the investors' desire to see solid growth and profitability in the long run.
However, it is essential to understand that the pharmaceutical industry is highly competitive, which means that many significant companies operate in this space. These companies tend to have diversified product portfolios, expansive distribution networks, and significant marketing budgets, which can help secure their market share and profitability.
It is noteworthy that Shuttle Pharmaceuticals Holdings Inc is a rising player in the pharmaceutical industry, which means that the company is still finding its feet in the market. The most crucial measure of the company's growth and profitability in the long run will stem from the successful development, approval, and commercialization of its pipeline products.
|
| Per Share |
Current |
| Earnings (TTM) |
-1.66 $ |
| Revenues (TTM) |
21.7 $
|
| Cash Flow (TTM) |
- |
| Cash |
4.1 $
|
| Book Value |
19.03 $
|
| Dividend (TTM) |
0.08 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.66 $
|
| Revenues (TTM) |
21.7 $ |
| Cash Flow (TTM) |
- |
| Cash |
4.1 $
|
| Book Value |
19.03 $ |
| Dividend (TTM) |
0.08 $ |
|
|
|
|
